Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Research

PDGF-BB accelerates TSCC via fibroblast lactates limiting miR-26a-5p and boosting mitophagy

Authors: Jianguo Xu, Li Bian, Dingyun You, Ziliang Li, Tingting Wang, Yiting Li, Xiaobin Ren, Yongwen He

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

The tumor microenvironment and cancer-associated fibroblasts (CAFs) play crucial roles in tumor development, and their metabolic coupling remains unclear. Clinical data showed a positive correlation between PDGF-BB, CAFs, and glycolysis in the tumor microenvironment of oral tongue squamous cell carcinoma patients. In vitro, CAFs are derived from hOMF cells treated with PDGF-BB, which induces their formation and promotes aerobic glycolysis. Mitophagy increased the PDGF-BB-induced formation of CAF phenotypes and aerobic glycolysis, while autophagy inhibition blocked PDGF-BB-induced effects. Downregulation of miR-26a-5p was observed in CAFs; upregulation of miR-26a-5p inhibited the expression of mitophagy-related proteins ULKI, Parkin, PINK1, and LC3 and aerobic glycolysis in PDGF-BB-induced CAFs. PDGF-BB-induced CAFs promoted tumor cell proliferation, invasion, metastasis, NF-κB signaling pathway activation, and PDGF-BB secretion. Thus, PDGF-BB is associated with lactate-induced CAF formation and glucose metabolism reprogramming. These findings indicate potential therapeutic targets in oral tongue squamous cell carcinoma.
Appendix
Available only for authorised users
Literature
1.
OCAñA MC, MARTíNEZ-POVEDA B, QUESADA A R, et al. Metabolism within the Tumor microenvironment and its implication on cancer progression: an ongoing therapeutic target [J]. Med Res Rev. 2019;39(1):70–113.CrossRefPubMed
2.
ELIA I, HAIGIS MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism [J]. Nat Metab. 2021;3(1):21–32.CrossRefPubMed
3.
MAO X, XU J, WANG W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the Tumor microenvironment: new findings and future perspectives [J]. Mol Cancer. 2021;20(1):131.CrossRefPubMedPubMedCentral
4.
HU H, LIU B, ZUO Y, et al. Dl-3-n-butylphthalide suppresses PDGF-BB-stimulated vascular smooth muscle cells proliferation via induction of autophagy [J]. Life Sci. 2016;151:182–8.CrossRefPubMed
5.
6.
HELDIN C H, LENNARTSSON J. Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis [J]. J Intern Med. 2018;283(1):16–44.CrossRefPubMed
7.
8.
VAUPEL P. Revisiting the Warburg effect: historical dogma versus current understanding [J]. J Physiol. 2021;599(6):1745–57.CrossRefPubMed
9.
ZHANG Z, GAO Z. Metabolic reprogramming of normal oral fibroblasts correlated with increased glycolytic metabolism of oral squamous cell carcinoma and precedes their activation into carcinoma associated fibroblasts [J]. Cell Mol Life Sci. 2020;77(6):1115–33.CrossRefPubMed
10.
CHENG A, ZHANG P, WANG B, et al. Aurora-A mediated phosphorylation of LDHB promotes glycolysis and Tumor progression by relieving the substrate-inhibition effect [J]. Nat Commun. 2019;10(1):5566.CrossRefPubMedPubMedCentral
11.
12.
ZHANG T, LIU Q, GAO W, et al. The multifaceted regulation of mitophagy by endogenous metabolites [J]. Autophagy. 2022;18(6):1216–39.CrossRefPubMed
13.
14.
GUSTAFSSON Å B, DORN G W 2ND. Evolving and expanding the roles of Mitophagy as a homeostatic and pathogenic process [J]. Physiol Rev. 2019;99(1):853–92.CrossRefPubMed
15.
XI L, PENG M, LIU S, et al. Hypoxia-stimulated ATM activation regulates autophagy-associated exosome release from cancer-associated fibroblasts to promote cancer cell invasion [J]. J Extracell Vesicles. 2021;10(11):e12146.CrossRefPubMedPubMedCentral
16.
HUANG M, FU M, WANG J et al. TGF-β1-activated cancer-associated fibroblasts promote breast cancer invasion, metastasis and epithelial-mesenchymal transition by autophagy or overexpression of FAP-α [J]. Biochem Pharmacol, 2021, 188(114527.
17.
GRANLUND K L, TEE S S, VARGAS H A et al. Hyperpolarized MRI of human Prostate Cancer reveals increased lactate with Tumor Grade Driven by Monocarboxylate Transporter 1 [J]. Cell Metab, 2020, 31(1): 105 – 14.e3.
18.
LU X, CHEN L, LI Y, et al. Long non-coding RNA LINC01207 promotes cell proliferation and migration but suppresses apoptosis and autophagy in oral squamous cell carcinoma by the microRNA-1301-3p/lactate dehydrogenase isoform a axis [J]. Bioengineered. 2021;12(1):7780–93.CrossRefPubMedPubMedCentral
19.
20.
WANG Z H, PENG W B, ZHANG P et al. Lactate in the tumour microenvironment: From immune modulation to therapy [J]. EBioMedicine, 2021, 73(103627.
21.
LAI Y, TANG F, HUANG Y, et al. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy [J]. J Cell Physiol. 2021;236(3):1616–27.CrossRefPubMed
22.
23.
TISATO V, ZAMBONI P. Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous Disease [J]. Cytokine. 2013;63(2):92–6.CrossRefPubMed
24.
LIU F L, MO E P YANGL, et al. Autophagy is involved in TGF-β1-induced protective mechanisms and formation of cancer-associated fibroblasts phenotype in Tumor microenvironment [J]. Oncotarget. 2016;7(4):4122–41.CrossRefPubMed
25.
ZHANG C, WANG X Y, ZHANG P, et al. Cancer-derived exosomal HSPC111 promotes Colorectal cancer liver Metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts [J]. Cell Death Dis. 2022;13(1):57.CrossRefPubMedPubMedCentral
26.
NURMIK M, ULLMANN P, RODRIGUEZ F, et al. In search of definitions: Cancer-associated fibroblasts and their markers [J]. Int J Cancer. 2020;146(4):895–905.CrossRefPubMed
27.
BERNARD M, DIEUDé M, YANG B, et al. Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF [J]. Autophagy. 2014;10(12):2193–207.CrossRefPubMed
28.
LI Z, SUN C. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming [J]. Theranostics. 2021;11(17):8322–36.CrossRefPubMedPubMedCentral
29.
LI S, GAO J, ZHUANG X, et al. Cyclin G2 inhibits the Warburg Effect and Tumour Progression by suppressing LDHA phosphorylation in glioma [J]. Int J Biol Sci. 2019;15(3):544–55.CrossRefPubMedPubMedCentral
30.
JIANG E, XU Z, WANG M, et al. Tumoral microvesicle-activated glycometabolic reprogramming in fibroblasts promotes the progression of oral squamous cell carcinoma [J]. Faseb j. 2019;33(4):5690–703.CrossRefPubMed
31.
WANG X, LIU H, NI Y, et al. Lactate shuttle: from substance exchange to regulatory mechanism [J]. Hum Cell. 2022;35(1):1–14.CrossRefPubMed
32.
JENA B C, ROUT L, DEY A, et al. Active autophagy in cancer-associated fibroblasts: recent advances in understanding the novel mechanism of Tumor progression and therapeutic response [J]. J Cell Physiol. 2021;236(11):7887–902.CrossRefPubMed
33.
SANCHEZ C G, PENFORNIS P, OSKOWITZ A Z, et al. Activation of autophagy in mesenchymal stem cells provides Tumor stromal support [J]. Carcinogenesis. 2011;32(7):964–72.CrossRefPubMedPubMedCentral
34.
LIU Y, HU T. Separation, cultivation and biological characteristics of oral carcinoma-associated fibroblasts [J]. Oral Dis. 2006;12(4):375–80.CrossRefPubMed
35.
CHEN Z, LI Y, ZHANG H, et al. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression [J]. Oncogene. 2010;29(30):4362–8.CrossRefPubMed
36.
PUISSéGUR MP, MAZURE N M, BERTERO T, et al. miR-210 is overexpressed in late stages of Lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity [J]. Cell Death Differ. 2011;18(3):465–78.CrossRefPubMed
37.
38.
JIN F, WANG Y, LI M, et al. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy [J]. Cell Death Dis. 2017;8(1):e2540.CrossRefPubMedPubMedCentral
Metadata
Title
PDGF-BB accelerates TSCC via fibroblast lactates limiting miR-26a-5p and boosting mitophagy
Authors
Jianguo Xu
Li Bian
Dingyun You
Ziliang Li
Tingting Wang
Yiting Li
Xiaobin Ren
Yongwen He
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03172-6

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

C6orf15 promotes liver metastasis via WNT/β-catenin signalling in colorectal cancer

Research

Disulfidptosis-related signature predicts prognosis and characterizes the immune microenvironment in hepatocellular carcinoma

Review

Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors

Research

The therapeutic effect of a novel GAPDH inhibitor in mouse model of breast cancer and efficacy monitoring by molecular imaging

Research

Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways

Research

USP29 activation mediated by FUBP1 promotes AURKB stability and oncogenic functions in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits